Universitatsklinikum Schleswig Holstein Ii Medizinische Klinik & Poliklinik

Kiel, Germany

Universitatsklinikum Schleswig Holstein Ii Medizinische Klinik & Poliklinik

Kiel, Germany
SEARCH FILTERS
Time filter
Source Type

Knecht H.,Universitatsklinikum Schleswig Holstein Ii Medizinische Klinik & Poliklinik | Fullgrabe M.,Universitatsklinikum Schleswig Holstein Ii Medizinische Klinik & Poliklinik | Trautmann H.,Universitatsklinikum Schleswig Holstein Ii Medizinische Klinik & Poliklinik | Herrmann D.,Universitatsklinikum Schleswig Holstein Ii Medizinische Klinik & Poliklinik | And 4 more authors.
BioSpektrum | Year: 2015

Minimal residual disease (MRD) has become an important tool for risk assessment and treatment stratification in hematological malignancies such as acute lymphoblastic leukemia (ALL). Currently, MRD is under discussion as new endpoint in clinical trials. Allele-specific real-time quantitative RQ-PCR is the gold standard for molecular quantification of clonal immunoglobuline and T-cell receptor (IG/TCR) gene rearrangements but next generation sequencing may overcome current limitations of IG/TCR based MRD assessment. © 2015, Springer-Verlag Berlin Heidelberg.

Loading Universitatsklinikum Schleswig Holstein Ii Medizinische Klinik & Poliklinik collaborators
Loading Universitatsklinikum Schleswig Holstein Ii Medizinische Klinik & Poliklinik collaborators